Novelos’s NOV-002 has demonstrated positive results in Phase II trials for other oncology indications.
Overall, Novelos filed more than 30 patent applications worldwide. Together, these will provide broad and long-lasting coverage, up to at least 2019, encompassing composition of matter, method of use and manufacturing for Novelos’s compounds.
Christopher Pazoles, vice president of R&D at Novelos, said: “This most recent addition to our IP portfolio further strengthens Novelos’s proprietary position in the oxidized glutathione field in general and, in particular, around the structure of Nov-002.”